The effect of metformin therapy for patients with type 2 diabetes mellituson serum lipid levels

Background:Patients with diabetes mellitus often have dyslipidemia and accelerate atherosclerosis; therefore, effective management of dyslipidemia can lower death and morbidity rates while also improving the quality of life for these patients. When used by diabetic patients, lipid-lowering medications like statins can have a number of negative side effects that worsen quality of life in addition to providing less-than-ideal results.Aim of the study:this study aim to investigate how metformin medication affected the blood lipid levels of individuals with type 2 diabetes.Methods:Forty-five type 2 diabetes patients, ranging in age from thirty to less than sixty, were involved in this study. For two months, patients received 500 mg of metformin orally (Glucomet, Furat Pharmaceutical Industries, Iraq). The total cholesterol, triglyceride, and HDL levels were measured using the Abbott, USA Cholesterol, Triglyceride, and HDL kits. The methods followed the guidelines supplied by the supplier.Results:The study compared the average levels of serum lipids before and after treatment. The results indicated that there were no significant changes in mean serum cholesterol, high density lipoprotein (HDL), and low density lipoprotein (LDL) (p > 0.05). However, there was a significant decrease in very low density lipoprotein (VLDL) (p < 0.001) and triglyceride levels (p < 0.001), which decreased from 220.69 87.61 mg/dl to 165.21 66.50 mg/dl.Conclusion:Metformin medicine is efficient and safe in reducing blood triglyceride levels in persons with type 2 diabetes mellitus, although a longer treatment duration may be necessary to obtain similar results for LDL and total cholesterol levels.